Verastem, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VSTM research report →
Range $12 – $22
Price Chart
About the company
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism.
- CEO
- Daniel W. Paterson
- IPO
- 2012
- Employees
- 102
- HQ
- Needham, MA, US
Get TickerSpark's AI analysis on VSTM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $797.67M
- P/E
- -4.01
- PEG
- -0.04
- P/S
- 9.31
- P/B
- 74.27
- EV/EBITDA
- -5.03
- Div Yield
- 0.00%
- Gross Margin
- 86.11%
- Op Margin
- -193.73%
- Net Margin
- -178.38%
- ROE
- -359.49%
- ROIC
- -145.58%
Latest fiscal year · YoY change
- Revenue
- $30.91M+209.1%
- Gross Profit
- $25.62M+156.2%
- Op Income
- $-170,129,000
- Net Income
- $-209,471,000-60.3%
- EPS
- $-3.02+17.5%
- OCF Growth
- -31.2%
- FCF Growth
- -31.2%
- 52W High
- $10.82
- 52W Low
- $3.43
- 50D MA
- $8.43
- 200D MA
- $6.31
- Beta
- 0.32
- RSI (14)
- 28
- Avg Volume
- 3.49M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Verastem posted $24.0 million of third-quarter net product revenue, advanced its AVMAPKI FAKZYNJA launch and VS-7375 pipeline, and ended the quarter with a strengthened balance sheet that it says funds operations into the first half of 2028.· November 5, 2026
- Q3 net product revenue was $24.0 million, up 114% year over year, driven by AVMAPKI FAKZYNJA CO-PACK refills and broader prescribing.
- The company said the CO-PACK launch is benefiting from expanding physician adoption, but new patient starts moderated after strong Q2 growth and late-summer seasonality.
- FDA accepted the new blister-pack NDA with priority review and a February 2027 PDUFA date, which management says should improve convenience and adherence.
- VS-7375 data in KRAS G12D cancers were presented as encouraging across pancreatic, colorectal and lung cohorts, with management calling the profile potentially best-in-class.
- Verastem raised about $250 million gross in October and said its cash plus expected CO-PACK revenue should fund operations into the first half of 2028.
For the third quarter of 2026, Verastem reported net product revenue of $24.0 million, a 114% increase versus the third quarter of 2025. Product cost of sales was $3.7 million, research and development expense was $68.8 million, and SG&A expense was $26.5 million. Non-GAAP adjusted net loss was $72.8 million, or $0.72 per diluted share, compared with a non-GAAP adjusted net loss of $39.1 million, or $0.53 per diluted share, in the prior-year quarter. The company ended Q3 with $172.8 million in cash, cash equivalents and investments; including the October financing, pro forma cash was $422.8 million. Management said that, based on current cash, the October follow-on offering and expected AVMAPKI FAKZYNJA revenue, Verastem believes it can fund operations into the first half of 2028. No formal company revenue or EPS guidance was given beyond that funding outlook.
Dan Paterson said the quarter reflected progress in both the commercial business and the VS-7375 development program. He emphasized that the company is sharpening its commercial efforts around adoption, earlier use and adherence in LGSOC, while also pursuing a broader development strategy for VS-7375 across pancreatic, colorectal and lung cancers. His tone was upbeat but measured, with repeated focus on execution, the FDA alignment on trial designs, and the significance of the recent financing in supporting multiple Phase II and Phase III programs.
Dan Calkins highlighted the key financials: $24.0 million of net product revenue, $3.7 million of product cost of sales, $68.8 million of R&D expense and $26.5 million of SG&A expense. He noted that R&D increased as expected due to the TARGET-D program and that SG&A was roughly in line with Q2, with the LGSOC franchise now self-sustaining from a commercial operations standpoint. He also said SG&A should remain consistent in Q4 2026 and reiterated the company’s liquidity position of $172.8 million at quarter-end, or $422.8 million pro forma including the October financing.
Analysts focused on the timing and form of upcoming VS-7375 updates, the pace of site openings for frontline PDAC, and whether the ORR-based frontline PDAC design differs meaningfully from competitors’ studies. Management said an update across the program is planned around the start of next year, with more medical-meeting updates to follow, and that the frontline PDAC trial is mainly delayed by logistics such as contracting and site initiation. On the design question, management argued the FDA was receptive because of the drug’s efficacy and tolerability, and said allowing crossover supports patient access while making OS a difficult endpoint to interpret.
Management believes AVMAPKI FAKZYNJA still has room to grow as more physicians gain experience, refills remain strong, and the blister-pack presentation could improve convenience and adherence. On the pipeline side, Verastem said VS-7375 showed compelling confirmed activity across pancreatic, colorectal and lung cancers, with a favorable safety profile and no Grade 4 or 5 treatment-related adverse events. The October financing also materially reduces near-term funding risk and supports multiple pivotal trials.
The commercial launch still faces quarter-to-quarter volatility, with new patient starts moderating after Q2 growth and management acknowledging the episodic nature of rare-disease treatment persistence. In pipeline development, much of the most important data remain early, and management repeatedly noted that CRC and lung readouts are still maturing. The company also faces competitive pressure in KRAS G12D and broader RAS programs, and management acknowledged that treatment patterns outside the approved LGSOC indication could shift as other therapies and trials evolve.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.6%
- Shares Outstanding
- 126.01M
- Float Shares
- 111.69M
of shares held by institutions
167 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 9.52M | ▲ 323.34K |
| Armistice Capital, LLC | 7.02M | ▲ 2.43M |
| Rtw Investments, LP | 6.64M | ▲ 59.49K |
| Deep Track Capital, LP | 5.74M | 0 |
| Vanguard Group Inc | 4.15M | ▲ 673.70K |
| State Street Corp | 4.02M | ▼ 1.11M |
| Rosalind Advisors, Inc. | 3.99M | ▲ 1.85M |
| Vanguard Capital Management LLC | 3.82M | ▼ 32.72K |
| Foresite Capital Management Vi LLC | 3.15M | 0 |
| Stonepine Capital Management, LLC | 3.04M | ▼ 306.85K |
| Goldman Sachs Group Inc | 2.72M | ▲ 1.24M |
| Vanguard Portfolio Management LLC | 2.56M | ▼ 710.95K |
Held by 145 ETFs
Biggest fund positions in VSTM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 3, 26 | Paterson Dan | sell | 1,299 |
| Sep 30, 26 | Paterson Dan | other | 106,893 |
| Oct 1, 26 | Paterson Dan | sell | 44,121 |
| Sep 30, 26 | Calkins Daniel | other | 8,333 |
| Oct 1, 26 | Calkins Daniel | sell | 2,566 |
| Sep 21, 26 | Calkins Daniel | sell | 55 |
| Aug 3, 26 | Paterson Dan | sell | 1,302 |
| Jun 22, 26 | Paterson Dan | sell | 20,871 |
| Jun 22, 26 | Calkins Daniel | sell | 4,032 |
| Jun 22, 26 | Calkins Daniel | sell | 57 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VSTM coverage
Recent articles, reports, and earnings notes.
No research on VSTM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VSTM report →Verastem Oncology Announces Late-Breaking Oral Presentation of VS-7375 Lung Cancer Data at IASLC/ASCO 2026 North America Conference on Lung Cancer
businesswire.com · Nov 18
Verastem Weighs Partnership or Solo Launch as Cancer Drug Trials Advance
marketbeat.com · Nov 16
Verastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval Path
marketbeat.com · Nov 11
Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans
marketbeat.com · Nov 10
What Verastem (VSTM) Said on Its Q3 Earnings Call
marketbeat.com · Nov 6
Verastem, Inc. (VSTM) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
Verastem (VSTM) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 5
Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
businesswire.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.